Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies

Journal of Nuclear Medicine

Volumn 38, Issue 5, 1997, Pages 731-741

  Zhu, Hui ^a,b   Baxter, Laurence T ^a,b   Jain, Rakesh K ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

antibody pharmacokinetics; mathematical modeling; radiation dosimetry; radioimmunodetection; radioimmunotherapy

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER SCINTISCANNING; COMPUTER SIMULATION; DOSIMETRY; MATHEMATICAL MODEL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY;

EID: 0030960042     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Goldenberg D, Larson S. Radioimmunodetection in cancer identification. J Nucl Med 1992;33:803-814.
2. Goldenberg DM. Introduction to the fifth conference on radioimmunodetection and radioimmunotherapy of cancer. Cancer Res 1995;55:5708s-5709s.
3. Larson SM. Improving the balance between treatment and diagnosis: a role for radioimmunodetection. Cancer Res 1995;55:5756s-5758s.
4. 2fragments against CEA studied in a human tumor xenograft model. Br J Cancer 1986;54:341-344.
5. Halpern S, Hagan P. Effect of protein mass on the pharmacokinetics of murinc monoclonal antibodies. J Nucl Med 1985;26:818-819.
6. van Dijk J, Zegveld ST, Fleuren GJ, Warnaar SO. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3; G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity. Int J Cancer 1991;48:738-743.
7. Endo K, Kamma H, Ogata T. Radiolabeled monoclonal antibody 15 and its fragments for localization and imaging of xenografts of human lung cancer. J Natl Cancer Inst 1988;80:835-842.
8. 2fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG. BrJ Cancer 1991;63:37-44.
9. Harwood PJ, Boden J, Pedley RB, Rawlins G, Gogers GT, Bagshawe KD. Comparative tumor localization of antibody fragments and intact IgG in nude mice bearing a CEA-producing human colon tumor xenograft. Eur J Cancer Clin Oncol 1985;21: 1515-1522.
10. Hendrix PG, Dauwe SE, van de Voorde A, Nouwen EJ, Hoylaerts MF, de Broe ME. Radiolocalization and imaging of stably HPLAP-transfected MO4 tumors with monoclonal antibodies and fragments. Br J Cancer 1991;64:1060-1068.
11. Milenic DE, Yokota T, Filpular DR, et al. Construction; binding properties; metabolism; and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 1991;51:6363-6371.
12. Nieroda CA, Milenic DE, Carrasquillo JA, Schlom J, Greiner JW. Improved tumor radioimmunodetection using a single-chain Fv and g-interferon: potential clinical applications for radioimmunoguided surgery and g scanning. Cancer Res 1995;55: 2858-2865.
13. 131I anti-CEA antibody in a colonie xenograft model. Br J Cancer 1993;68:69-73.
14. 99mTc: the role of metabolism and kinetics. Cancer Res 1995;55:5777s-5785s.
15. Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 1984;11:638-645.
16. Yorke E, Beaumier P, Wessels B, Fritzberg A, Morgan AC. Optimal antibodyradionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics. Nucl Med Biol 1991;18:827-835.
17. Sands H, Jones PL, Shah SA, Palme D, Vessella R, Gallagher BM. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human clouser and renal cell xenografts. Cancer Res 1988;48:188-193.
18. Baxter LT, Zhu H, Butler WF, Jain RK. Physiologically based pharmacokinetic model for specific and non-specific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 1994;54:1517-1528.
19. Baxter LT, Zhu H, Mackensen DG, Jain RK. Biodistribution of monoclonal antibodies: scale up from mouse to man using a physiologically based pharmacokinetic model. Cancer Res 1995;55:4611-4622.
20. Jain RK. Delivery of molecular medicine to solid tumors. Science 1996:271:1079 1080.
21. Dedrick R. Animal scale up. J Pharmacokin Biopharm 1973; 1:435-461.
22. Strand SE, Zanzonico P, Johnson T. Pharmacokinetic modeling. Med Phys 1993;20: 515-527.
23. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. Methotrexate pharmacokinetic. J Pharmacol Sei 1971 ;60:1128-1133.
24. Gerlowski LE, Jain RK. Physiologically based pharmacokinetic modeling: principles and applications. J Pharmacol Sei 1983;72:1103-1123.
25. Watson EE, Stabin G, Siegel JA. MIRD formulation. Med Phys 1993; 20:511-514.
26. Leichner PK, Kwok CS. Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles. Med Phys 1993;20:529-534.
27. Meredith RF, Johnson TK, Macey DJ, et al. Dosimetry of solid tumors. Med Phys 1993;20:583-592.
28. Bradwell AR, Fairweather DS, Dykes PW, Keeling A, Vaughan A, Taylor J. Limiting factors in the localization of tumors with radiolabeled antibodies. Immunol Today 1985;6:163-170.
29. Bradwell AR, Dykes P, Thomas G. Antibody targeting: theoretical considerations. In: Goldenberg DM, ed. Cancer imaging with radiolabeled antibodies. New York, NY: Kluwer Academic Publishers; 1990:11-25.
30. Rockoff SD, Goodenough D, Mclntire KR. Theoretical limitations in the immunodiagnostic imaging of cancer with computed tomography and nuclear scanning. Cancer Res 1980;40:3054-3058.
31. Roberson PL, Buchsbaum DJ. Reconciliation of tumor dose response to external beam radiotherapy versus radioimmunotherapy with I31f-labeled antibody for a colon cancer model. Cancer Res 1995;55:581 ls-5816s.
32. Langmuir VK, Fowler JF, Knox SJ, Wessels BW, Sutherland RM, Wong JYC. Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry. Med Phys 1993;20:601-610.
33. Phillips T. Principles of radiobiology and radiation therapy. In: Carter S, Glatstein E, Livingston R, eds. Principles of cancer treatment. New York, NY: McGraw-Hill; 1985:58-87.
34. Sands H, Gallagher BM. Physiological, pharmacological and immunological aspects of antibody targeting. In: Zalutsky MR, ed. Antibodies in radiodiagnosis and therapy. Boca Raton, FL: CRC Press; 1989:129-151.
35. Schlom J, Hand PH, Greiner JW, et al. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res 1990;50:820s-827s.
36. Buchsbaum DJ. Experimental approaches to increase radiolabeled antibody localization in tumors. Cancer Res 1995;55:5729s-5732s.
37. Knox SJ. Overview of studies on experimental radioimmunotherapy. Cancer Res 1995;55:5832s-5836s.
38. Carrasquillo JA, Sugarbaker P, Colcher D. Radioimmunoscintigraph of colon cancer with iodine-131-labeled B72.3 monoclonal antibody. J Nucl Med 1988;29:1022-1030.
39. Khaw B, Strauss HW, Narula J. "Magic bullets:" from muskets to smart bombs! J Nucl Med 1993;34:2264-2268.
40. Doerr RJ, Abdel-Nabi H, Krag D. Radiolabeled antibody imaging in the management of colorectal cancer. Ann Surg 1991;214:118-124.
41. Hellman S. Principles of radiation therapy. In: Rosenberg SA, Hellman S, De Vito V, eds. Cancer, vol. 1. Philadelphia, PA: J.B. Lippincott; 1992:2490.
42. Eger RR, Covell DG, Carrasquillo JA, et al. Kinetic model for the biodistribution of an "'in-labeled monoclonal antibody in humans. Cancer Res 1987;47:3328-3336.
43. Thomas GD, Chappell MJ, Dykes PW. Effect of dose, molecular size, affinity and protein binding on tumor uptake of antibody or ligand: a biomathematical model. Cancer Res 1989;49:3290-3296.
44. Sung C, Shockley TR, Morrison PF, Dvorak HF, Yarmush ML, Dedrick RL. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res 1992;52:377-384.
45. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2 and Fab in tumors. Cancer Res 1989;49:5656-5663.
46. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31: 1191-1198.
47. Fujimori K, Fisher DR, Weinstein JN. Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution. Cancer Res 1991;51:4821-4827.
48. Weinstein JN, Eger RR, Covell DG. The pharmacology of monoclonal antibodies. Ann NY AcadSci 1987;507:199-210.
49. Weinstein JN, van Osdol W. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding-site barrier." Cancer Res 1992;52:2747s-2751s.
50. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 1989;81:570-576.
51. Hindmarsh AC. LSODE and LSODI: two new initial value ordinary differential equation solvers. ACM Signum Newsletter 1980;15:10-11.
52. Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: the two-pore theory. Phys Rev 1994;74:163-219.
53. Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc Res 1990;41:5-23.
54. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988;48:26412658.
55. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987;47:3039-3051.
56. 2. J Nucl Med 1983;24:316-325.
57. 2fragment and whole IgG2a in human glioma xenografts. Cancer Res 1988;48:5701-5707.
58. 2fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med 1990;31:1035-1044.